Big pharma is getting smaller and more focused, not bigger, and now Merck & Co. Inc. is the latest company to announce that it will spin out its more mature pharmaceutical products. Merck announced on 5 February that it will spin off its women's health, legacy brands and biosimilars into a new publicly traded company.
Merck will remain focused on its high-growth drivers: oncology – namely the PD-1 inhibitor Keytruda (pembrolizumab), vaccines, hospital and animal...